2022
Aurigene Pharmaceutical Services Launches its New Branding at CPHI North America
Aurigene has been established as a wholly-owned subsidiary of Dr. Reddy’s through the merger of Aurigene Discovery Services and Dr. Reddy’s Custom Pharma Services (CPS). The launch of the brand happened during the pandemic and it is therefore the first opportunity for the team to exhibit the new brand to its customers.
Read MoreAurigene Pharmaceutical Services, Dr. Reddy's Laboratories and DNDi to explore joint opportunities to develop affordable and life-saving new drugs for Neglected Tropical Diseases
Potential partnership to explore new therapeutic solutions and serve unmet needs of patients in Neglected Tropical Diseases in LMICs and beyond.
Read More2021
DeepMatter to trial its DigitalGlassware® platform with Aurigene Pharmaceutical Services
DeepMatter Group Plc (AIM: DMTR, “Deepmatter”, the “Group”), the international digital chemistry data company, has signed a trials agreement with Aurigene Pharmaceutical Services Limited (“Aurigene Pharmaceutical Services”), based in Hyderabad, India, to supply its DigitalGlassware® platform.
Read MoreAurigene Pharmaceutical Services Limited (APSL) invests in adding Large Molecule Discovery and Development Services
Aurigene Pharmaceutical Services Limited, a wholly-owned subsidiary of Dr. Reddy’s expands its existing discovery and development capacities with the inauguration of a biotherapeutics discovery facility in Hyderabad, India.
Read MoreAurigene Pharmaceutical Services is
a leading CRO/CDMO
that provides contract research, development and manufacturing services
Contact UsResources
Oligonucleotide as a novel class of therapeutic modality
JULY 02, 2021
The influence of formulation development and its route of administration
JANUARY 04, 2021
Technology meets sustainability - How a complex API development process goes green
Accelerating Drug Discovery Through Innovative Partnerships
Evolution in Pharma Industry and Demand for Integrated CDMO
Peptide Development and Manufacturing
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.